Arndt Vogel,Β Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X:
“10-year follow up for Pembrolizumab in MSI-H/dMMR advanced solid tumors:
KEYNOTE 16
-
10-yrs OS rate: 46%
-
Rare progression after 2 years.
-
We need biomarker to identify (non-) responders.
-
Great to see 10yr survival data for systemic therapies.”
Arndt Vogel highlighted 10-year overall survival results from the KEYNOTE-16 trial, showing a 46% survival rate with pembrolizumab in MSI-H/dMMR advanced solid tumors. He pointed out the rarity of progression after two years and the ongoing need for biomarkers to predict treatment response.
More posts featuringΒ Arndt Vogel.
